Skip to content
Screener

LivaNova LIVN Neuromodulation — Cost of Sales

Other segment segments

Cardiopulmonary
$97.27M+1.9%

Similar metrics at other companies

Dutch Bros logo
BROSLabor costs — Cost of Sales
$129.46M+27.8%
Target logo
TGTMerchandising Cost of Sales — Cost of Sales
$16.28B+6.0%
The Chef's Warehouse logo
CHEFFood Processing Costs — Cost of Sales
$15.45M-6.5%
Dutch Bros logo
BROSOccupancy & other costs — Cost of Sales
$83.09M+38.5%
Dutch Bros logo
BROSPre-opening costs — Cost of Sales
$8.41M+85.1%
Solventum logo
SOLVCost of product — Cost of Sales
$807M-6.7%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemCardiopulmonary / Three Months Ended June 30, 2026Cardiopulmonary / Three Months Ended June 30, 2025Neuromodulation / Three Months Ended June 30, 2026Neuromodulation / Three Months Ended June 30, 2025
Net revenue$221,576$199,272$166,945$151,670
Less:
Cost of sales97,26595,46514,45514,769
Selling, general, and administrative66,46556,01256,56851,097
Research and development18,37616,46534,98729,784
3T litigation provision11,318(77)
$28,152$31,407$60,935$56,020
CardiopulmonaryNeuromodulation

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's neuromodulation — cost of sales?
LivaNova (LIVN) reported neuromodulation — cost of sales of $14.46M in Q2 2026.
How has LivaNova's neuromodulation — cost of sales changed year-over-year?
LivaNova's neuromodulation — cost of sales decreased by 2.1% year-over-year, from $14.77M to $14.46M.
What is the long-term trend for LivaNova's neuromodulation — cost of sales?
Over 3 years (2022 to 2025), LivaNova's neuromodulation — cost of sales has grown at a 20.9% compound annual growth rate (CAGR), from $31.62M to $55.82M.
What does neuromodulation — cost of sales mean?
Includes the direct costs attributable to the production and delivery of neuromodulation devices, such as raw materials, manufacturing labor, and overhead. Monitoring this helps assess the segment's gross margin performance and manufacturing cost control.

Ask your AI about LivaNova's neuromodulation — cost of sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude